Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An antifungal acquisition
December 2019
SHARING OPTIONS:

HALIFAX, Nova Scotia—Appili Therapeutics Inc. expanded its pipeline last month with the acquisition of T-2307 (now known as ATI-2307) under an agreement with FUJIFILM Toyama Chemical Co. Ltd. Appili gains exclusive worldwide rights (ex-Japan) to develop and commercialize ATI-2305, and in return will make future regulatory and commercial milestone payments to FUJIFILM Toyama Chemical, as well as a royalty on any net sales. The compound is a novel, broad-spectrum antifungal agent that is not currently susceptible to existing resistance mechanisms. ATI-2307 has shown broad-spectrum activity in vitro and in vivo against fungi such as Cryptococcus and multi-drug-resistant Candida. Appili plans to focus initially on advancing the compound as a treatment for cryptococcal meningitis. So far, ATI-2307 has been evaluated in three Phase 1 clinical studies showing it to be well tolerated in humans at anticipated dose levels.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.